Replies to post #26586 on Marker Therapeutics Inc (MRKR)

[Phantom Lord]

I would assume an offer will come as well. I just don't believe it will be anytime soon. I think a more reasonable scenario, given that Peter told me this himself, is that they continue the pancreatic trials with a partner. Obviously this would depend on what kind of a deal BP brings to the table. If this were to happen it would definitely further delay any future buyout. Until our share appreciates into the $5B range I don't see any buyout even being a possibility. We all know the company should be worth way more right now and so do they. No one would offer $100-$200 a share right now as that would be a valuation of ~$7B-$14B for a company trading around ~$270M. I know you said it's a big if but I just wanted to put valuations to the share prices. Either way a partnership is more plausible at this point but I wouldn't expect it to be until late next year at the earliest if at all.

[Inoviorulez]

For TPIV 200 in ovarian cancer results are expected Q4 2019 by the way. So that's another catalyst as well.

[microcapbiotech]

I respect your opinion and agree on the part concerning Tapimmune legacy drugs.
Please see post #26595 for a further of my reasoning.